睾酮治疗可阻止性腺功能减退男性从糖尿病前期进展为2型糖尿病:注册研究8年数据
结果显示治疗组HbA1c下降0.39±0.03%(P<0.0001)且90%血糖恢复正常,而未治疗组HbA1c升高0.63±0.1%(P<0.0001)且40.2%进展为2型糖尿病(HbA1c>6.5%)。睾酮治疗还改善多项代谢指标和症状评分,并降低死亡率(7.4% vs 16.1%,P<0.05)和非致死性心肌梗死发生率(0.4% vs 5.7%,P<0.005)。
要点
- 睾酮治疗使90%糖尿病前期合并性腺功能减退男性血糖恢复正常,未治疗组40.2%进展为糖尿病。
- 治疗组HbA1c下降0.39%,未治疗组升高0.63%,组间差异显著。
- 睾酮治疗还改善血脂、空腹血糖及AMS评分,并降低死亡率和非致死性心梗风险。
核心结论
- 长期睾酮治疗完全阻止性腺功能减退男性从糖尿病前期进展为2型糖尿病,并改善血糖、血脂和AMS评分。
主要发现
- 治疗组HbA1c下降0.39±0.03%(P<0.0001),未治疗组升高0.63±0.1%(P<0.0001)。
- 治疗组90%血糖恢复正常(HbA1c<5.7%),未治疗组40.2%进展为2型糖尿病(HbA1c>6.5%)。
- 治疗组死亡率7.4%,未治疗组16.1%(P<0.05)。
- 治疗组非致死性心肌梗死发生率0.4%,未治疗组5.7%(P<0.005)。
- 睾酮治疗还显著改善空腹血糖、甘油三酯与HDL比值、甘油三酯-葡萄糖指数、脂质蓄积指数、总胆固醇、LDL、HDL、非HDL、甘油三酯及AMS评分,而未治疗组这些参数均显著恶化。
关键数值与推荐
- 糖尿病前期定义为HbA1c 5.7-6.4%。
- 性腺功能减退定义为总睾酮≤12.1 nmol/L并伴有症状。
- 2型糖尿病定义为HbA1c>6.5%。
临床怎么用
- 对糖尿病前期合并性腺功能减退的男性,可考虑长期睾酮治疗以预防2型糖尿病并改善代谢指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND METHODS: Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7-6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years. RESULTS: HbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c <5.7%). In the untreated group, 40.2% progressed to T2D (HbA1c >6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males' Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005). CONCLUSIONS: Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.
引用
- Yassin A, Haider A, Haider KS, et al. Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. Diabetes Care. 2019. PMID: 30862651. doi:10.2337/dc18-2388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。